Joint Unit CIPF-Incliva

Spain

1 October 2019 - 30 September 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Joint Unit CIPF-Incliva published between 1 October 2019 - 30 September 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Research collaboration: Joint Unit CIPF-Incliva is a research collaboration whose article contributions are accrued to its participating partner institutions.

Note: Articles may be assigned to more than one subject area.

Count Share
1 0.22

Outputs by subject (Share)

Subject Count Share
Life Sciences 1 0.22

Top articles by Altmetric score in current window

Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.

Proceedings of the National Academy of Sciences of the United States of America

2019-11-21

1 October 2019 - 30 September 2020

International vs. domestic collaboration by Share

  • 100% Domestic
  • 0% International

Note: Hover over the graph to view the percentage of collaboration.

Top 10 domestic collaborators by Share (4 total)

  • Joint Unit CIPF-Incliva, Spain
  • Domestic institution
  1. Institute of Health Carlos III (ISCIII), Spain (0.39)
    0.22
    0.17
  2. Biodonostia Health Research Institute (Biodonostia HRI), Spain (0.35)
    0.22
    0.13
  3. University of the Basque Country (UPV/EHU), Spain (0.31)
    0.22
    0.08
  4. Donostia University Hospital, Spain (0.31)
    0.22
    0.08

Top 10 international collaborators by Share (0 total)

  • Joint Unit CIPF-Incliva, Spain
  • Foreign institution

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Participating institutions

Joint Unit CIPF-Incliva is a research collaboration whose article contributions are accrued to its participating partner institutions below.

Return to institution outputs